Table 2 |
|
|
Characteristics of children started on antiretroviral treatment (n = 315) |
|
|
Age at starta |
7.2 (4.5 – 10.4) |
|
< 3 yearsb |
38 (12%) |
|
3 – 4.9 yearsb |
51 (16%) |
|
5 – 14.9 yearsb |
226 (72%) |
|
Sex (male/female)b |
157/158 (50/50%) |
|
Clinical WHO-stageqb |
|
|
WHO stage I |
43 (13.7%) |
|
WHO stage II |
145 (46.0%) |
|
WHO stage III |
115 (36.5%) |
|
WHO stage IV |
12 (3.8%) |
|
Weight for age (Z-score) (n = 293)a |
-1.9 (-3.0;-0.9) |
|
Baseline CD4 count % (n = 282)a |
14 (9–18) |
|
< 15%b |
158 (56.0%) |
|
15–25%b |
118 (41.8%) |
|
> 25%b |
6 (2.1%) |
|
Baseline absolute CD4 counts (n= 302)a |
345 (229–572) |
|
Baseline hemoglobin (mg/dl)(n = 268)a |
11.0 (10.3–11.8) |
|
ART regimenb |
|
|
d4T/3TC/NVP |
281 (89.2%) |
|
d4T/3TC/EFV |
6 (1.9%) |
|
AZT/3TC/NVP |
19 (6.0%) |
|
AZT/3TC/EFV |
9 (2.9%) |
|
Time on ART (years)c |
2.0 (1.2–2.6) |
|
Total patient years of follow-up |
598 |
|
On tablets (FDC) |
577 |
|
On syrup |
21 |
|
< 1 year vs. ≥ 1 yearb |
59 (19 %) vs 256 (81 %) |
|
|
|
|
a Values are expressed as median (interquartile range) b Values are expressed as n (%) c As of June 30/2007 (closing date of dataset) WHO: world health organization; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; AZT: zidovudine; FDC: fixed-dose combination |
|
|
van Griensven et al. BMC Pediatrics 2008 8:39 doi:10.1186/1471-2431-8-39 |
|
